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Abstract: Infectious disease caused by pathogenic bacteria continues to be the primary challenge
to humanity. Antimicrobial resistance and microbial biofilm formation in part, lead to treatment
failures. The formation of biofilms by nosocomial pathogens such as Staphylococcus aureus (S. aureus),
Pseudomonas aeruginosa (P. aeruginosa), and Klebsiella pneumoniae (K. pneumoniae) on medical devices
and on the surfaces of infected sites bring additional hurdles to existing therapies. In this review, we
discuss the challenges encountered by conventional treatment strategies in the clinic. We also provide
updates on current on-going research related to the development of novel anti-biofilm technologies.
We intend for this review to provide understanding to readers on the current problem in health-care
settings and propose new ideas for new intervention strategies to reduce the burden related to
microbial infections.
Keywords: biofilms; anti-biofilms; nosocomial pathogens; Staphylococcus aureus; Pseudomonas
aeruginosa; Klebsiella pneumoniae
1. Microbial Biofilms and the Challenges in Infectious Disease
Bacterial infections remain a threat to human health despite the progress made in improving
the quality of health care, and continuous development of antibiotics and vaccines to control disease.
Bacterial infections can occur at any stage in human life and can often be controlled by a healthy
immune system of the host. During hospitalization, patients are exposed to pathogen sources within
the environment including medical equipment, other infected patients, and healthcare staff and are
thus susceptible to hospital-acquired infections (HAI) [1]. Immunocompromised patients, the elderly
or patients with existing chronic disease such as diabetes, cancer, cardiovascular diseases, or breakage
of skin barrier such occurs with wounds, are reported to face a higher risk of nosocomial infection [2].
The typical medical device associated with HAI are related to central line bloodstream infections,
ventilator pneumonia, and catheter urinary infections [1].
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The increasing trend of nosocomial bacterial infections in immunocompromised hospitalized
patients is worrying as HAI are the primary cause of morbidity in the health-care setting [3,4]. In the
United States alone, it was estimated that a total of 1.7 million HAI occurred in the year 2002 alone,
with 4.5 cases occurring for every 100 admissions, resulting in almost 99,000 deaths [5]. At the European
level, more than 2 million patients contracted HAI, with 175,000 deaths per year [6]. The incidence
of HAI are substantially lower at 7.1% and 4.5% in Europe and USA, respectively, compared to the
low and middle-income countries (LMICs), where the average prevalence of HAI is 15.5% [7]. Among
the leading bacteria that cause the HAI is Staphylococcus aureus (S. aureus), Pseudomonas aeruginosa
(P. aeruginosa), Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Acinetobacter baumanii,
Clostridium difficile, and Enterococci [8,9]. The ability of these bacteria to form biofilms at the infected
site or on medical devices has been increasingly recognized as one of the factors causing failure in the
treatment of HAI, with biofilms estimated to contribute to approximately half of HAI [8,10]. Figure 1
shows the common site of infections related to the formation of bacterial biofilms.
1.1. Methicillin-Resistant Staphylococcus aureus (MRSA)
Staphylococcus aureus is a Gram-positive cocci-shaped bacterium that forms part of the normal flora
on the body and is frequently isolated from the skin, respiratory tract, and female lower reproductive
tract [11,12]. Infections by S. aureus were once treatable by penicillin. However, increasing resistance
towards penicillin led to the introduction of methicillin for the treatment in 1960 [13]. However, soon
after that, S. aureus acquired resistance towards methicillin, giving rise to methicillin-resistant S. aureus
(MRSA) clones [12,13]. Currently, the Center for Disease Control (CDC) reported that infections by
MRSA are the second most common cause of HAI in the USA [14]. The most common route of MRSA
transmission is through direct contact. The ability of the organism to form biofilms on tissues such
as the skin and inert indwelling device surfaces such as intravenous catheters and surgical implants
further expose susceptible individuals [15]. Development of worldwide antibiotic resistance towards
first-line therapies such as vancomycin and teicoplanin continues to hinder and restrict the successful
treatment of MRSA infection [15]. Additionally, S. aureus also can invade host cells and evade the
antimicrobial effects of administered therapies [16]. Together, these characteristics allow this organism
to remain an important pathogen.
1.2. Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative, rod-shaped, facultative anaerobe ubiquitous in the environment
and forms part of the normal gut flora. Increasing resistance towards the multiple antibiotics, e.g.,
cephalosporins and carbapenem further compounds the problem due to the emergence of extremely
drug-resistant (XDR) P. aeruginosa infections [17,18]. The last available treatment resort is colistin,
a polymyxin antibiotic which was avoided for the past three decades as it may cause both neuro-
and nephrotoxicity [19–21]. Patients dependent on breathing machines or fitted with an invasive
device such as a catheter, are at risk of severe and life-threatening illness from P. aeruginosa capable
of forming biofilms on medical device surfaces [22–25]. P. aeruginosa biofilms were reported to cause
endocardial valve infection through endocardial tubes, ventilator-associated pneumonia (VAP), and
catheter-associated urinary tract infections (CAUTI). Additionally, P. aeruginosa has also been reported
to be able to grow in intravenous fluid and could enter the bloodstream and cause sepsis [26–28].
1.3. Klebsiella pneumoniae
Klebsiella pneumoniae (K. pneumoniae) is a non-fastidious, Gram-negative bacillus, and is usually
encapsulated. The bacterium is one of the normal flora present in the mouth, skin, and intestine, yet
it has been reported to cause pneumonia, urinary tract infections, and bacteremia in patients from
hospitals, nursing homes, and other healthcare facilities [18]. K. pneumoniae is known as a remarkably
resilient pathogen as it can evade and survive rather than actively suppress many components of the
immune system of the infected host [29]. The bacteria have developed resistance towards almost all
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available antibiotics; fluoroquinolones, third-generation cephalosporins and aminoglycosides [30].
Recently, the emergence of the carbapenem-resistant K. pnemoniae strains which currently circulating
across the globe has forced the administration of colistin, an old and considered the last available
antibiotic [31]. Additionally, resistance towards colistin was recently reported, showed that the bacteria
are capable of evading all types of available antibiotics, leaving no drugs left for the treatment [32].
Compounding the problem, this organism can survive and grow within the intravenous fluid and
form biofilm on medical devices such as the urinary catheter, leading to detrimental septicemia in
patients [26,33–35].
2. The Physiology of Biofilms
2.1. Definition and the Structure of the Biofilm
Biofilms have been described in environmental and technical microbiology for more than 90 years.
However, the importance of microbial biofilms in medicine has only been recognized since the early
1980s [36]. A microbial biofilm is defined as a structured consortium of microbial cells surrounded by
the self-produced matrix [37]. The rough structure can be described as polymicrobial aggregates that
resemble mats, flocs, or sludge that accumulate at interfaces. Because of the soft and fragile structure,
it is difficult to physically characterize the structure from the infected or adhered surfaces in-vivo. Thus,
characterizations of biofilm were mostly performed using in-vitro cultured biofilm cells. The thickness
of biofilms can vary depending on the species of the bacteria, the duration and the method used
to grow the biofilm. In-vitro, the biofilms of P. aeruginosa can reach 209 µm; S. aureus, 8.0 µm; and
K. pneumoniae, 231 µm [33,38,39]. Figure 2 shows the three-dimensional structure of S. aureus biofilms
visualized with a confocal microscope with the thickness of approximately 8.0 µm.
Biofilms are built of planktonic (individual) bacterial cells ‘glued’ together with self-released
extra-polymeric substances (EPS) which consists of lipopolysaccharides, proteins, lipids, glycolipids,
and nucleic acids [40]. The type of polysaccharides found within the biofilm depends on the bacteria
species, S. aureus and S. epidermidis produce poly-ß(1,6)-N-acetyl-D-glucosamine (PNAG) [41], while
P. aeruginosa produces Pel (a cationic exopolysaccharide composed of 1–4 linked galactosamine
and glucosamine sugars) and Psl (a penta-saccharide composed of D-glucose, D-mannose and
L-rhamnose) [42,43]. The nucleic acid found in EPS is known as extracellular DNA (eDNA), generated
by lysis of a subpopulation of the same bacteria under the control of quorum sensing, a mode of
communication between cells. The role of EPS is to promote adhesion and aggregation of bacteria
to the surfaces and provides stability to the biofilm structure. Direct interaction of eDNA with
extracellular calcium (Ca2+) within the biofilm induces bacterial aggregation via cationic bridging.
The positive charge of the extracellular Ca2+ modifies the bacterial cell surface charge by neutralizing
the electrostatic repulsion between negatively charged biofilm components, thus assisting cellular
aggregation and adherence of bacteria to material and tissue surface [44,45]. Once the biofilm
is established, negatively charged eDNA acts as a biofilm defence mechanism by chelating the
cationic antimicrobial peptides from the host immune system. eDNA also chelates divalent cations
triggering the bacterial transcription of genes responsible for increasing pathogenicity and resistance
to antimicrobials [46].
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Figure 2. The three-dimensional structure of S. aureus biofilms visualized with a confocal microscope.
S. aureus biofilms were cultured in tryptic soy broth for 48 hours, fixed with 4% paraformaldehyde
and treated with wheat germ agglutinin (WGA, red) to stain n-acetylglucoseamine component of
polysaccharide and DAPI (blue) to stain the bacteria nuclear material, followed by confocal microscopy
z-stack projection that moved through 111 slices across the cell. (a) Horizontal cross-section of biofilms
and (b) Vertical cross-section of biofilms. White scale bar is 7.5 µm. The approximate thickness of the
biofilms was 7.9 ± 0.5 µm. Image adapted from Kamaruzzaman et al., 2017 [39].
2.2. Development of Biofilm
Development of biofilms generally involves several stages, represented schematically in Figure 3.
(1) Attachment of cells to surfaces: In this step, bacteria use eDNA and organelles and proteins (such
as flagella, pili, fimbriae, and outer membrane proteins) that can assist in sensing and attaching
to surfaces [47]; (2) Adhesion between cells and surfaces: Here, the EPS components consisting of
DNA, lipoproteins, and lipids secreted by the bacteria encourages cell to cell and cell to surface
adhesion; (3) Replication of cell and formation of microcolonies: In this stage, the bacteria become
encapsulated in a layer of hydrogel, which functions as a physical barrier between the community
and the extracellular environment. The bacteria within the community communicate with each other
through quorum sensing (QS), a chemical communication chemical signal that modulates cellular
functions, including pathogenesis, nutrient acquisition, conjugation, motility, and production of
secondary metabolites [48,49]. Within this stage, the biofilm will mature as cells replicate and EPS
accumulates; (4) Cell detachment from biofilms: The final stage involves the detachment of bacterial
cells from the microcolonies. Cells are then capable of forming a new biofilm colony at another
location [50,51].
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2.3. Mechanism of Antibiotic Resistance in Microbial Biofilms
Bacterial cells existing as biofilms can be 10–1000 times more resistant to antibiotics [52–54].
This condition is attributed by several factors and briefly summarised in Table 1. An excellent review on
detailed mechanism of biofilm mediated antimicrobial resistance and tolerance was recently published
by Hall & Mah (2017), thus readers are invited to refer to this article for detailed information [55].
Table 1. Mechanism of biofilm-mediated antimicrobial resistance.
Physiology of Biofilm Mechanism of Antimicrobial Resistance References
Component of the biofilm matrix
• Thick biofilm matrix • Reduced permeation of antimicrobials across
biofilm matrix
[52,54,56,57]
• Expression of polysaccharide
subunits in biofilm matrix
• Expression of PsI polysaccharides in P. aeruginosa
sequesters antimicrobials in the biofilm matrix via
electrostatic interaction
[42]
• Expression of antimicrobial
modifying enzymes in the
biofilm matrix
• Beta lactamases produced by Klebsiella pneumoniae
biofilm degrade beta lactam antibiotics [58]
• Expression of eDNA • eDNA interacts with antimicrobials and prevent furtherpenetration of the agent across the biofilm matrix to
reach cellular targets
[59]
Nutritional factors
• Oxygen deprived environment
• Deeper layer of the biofilm is oxygen deprived (hypoxic).
Hypoxic conditions reduce outer membrane potential of
bacteria, diminishing intracellular transport of antibiotics
into the bacterial cells
• Hypoxia induces increased (or is new expression?)
expression of bacterial membrane efflux pumps,
potentially reducing antimicrobial accumulation in
the cell
[60–62]
• Amino acid deprived environment • Amino acid starvation activates a stringent response in
bacteria within biofilm increasing antimicrobial tolerance
[57]
Physiology of bacteria
• Small colony variants and
persister cells
• Surviving bacteria within the biofilm may change into
small colony variants and persister cells. These variants
present different phenotypes compared to the wild type
planktonic cells including greater tolerance
towards antimicrobials
[63]
Table adapted from Hall & Mah (2017) [55].
2.4. Immune Evasion of Biofilms
Bacteria within the biofilm can evade recognition by the innate immune system and thus avoid
being eliminated or controlled by the immune system. While the purpose of this article is not to
provide a comprehensive review of immune evasion of biofilms, there are aspects worth comment in
the context of novel therapies and control strategies. We direct the reader to reviews by Roilides et al.,
Le et al., and Gunn et al. for more extensive information [64–66]. Despite a clear shortage of studies
concerning biofilm recognition by the immune system compared to planktonic cells, several common
evasion mechanisms have been described. Biofilms evade the natural antimicrobial properties of innate
immune cells by thwarting pathogen recognition, phagocytosis, and cellular activation [67]. In some
cases, the cells of the innate immune system assist the process of biofilm growth and maturation [68].
Biofilms modulate leukocyte function by reducing phagocytosis, despite active migration of cells
towards the biofilm. Phagocytosis rates of biofilm material are thought to be diminished through a
lack of microbial recognition by pattern recognition receptors due to concealed or obscured bacterial
ligands such as lipoproteins, lipopolysaccharides, and nucleic acids (i.e., though EPS protection) [69].
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EPS protection also retains bacterial content within the biofilm, resulting in large complexes which
leukocytes are incapable of engulfing. Detached or homogenised (via sonication) bacteria from
biofilms are readily phagocytosed suggesting that leukocyte modulation is temporary [67]. Leukocyte
antimicrobial function and killing via oxidative burst (production of reactive oxygen species and nitric
oxide) is generally considered to be greatly reduced when considering responses against biofilms [70].
Oxidative burst is readily linked to reduced receptor mediated recognition, further highlighting the
role of the protective function of the biofilm matrix in immune evasion.
Experimental investigations with relevant HAI associated biofilms such as those of S. aureus and
P. aeruginosa continue to enhance the knowledge surrounding immune recognition in the context of
biofilms. Neutrophils are attracted to and migrate towards both S. aureus and P. aeruginosa biofilms
upon which a reduced phagocytic behaviour is observed along with decreased microbial killing [67].
Lack of S. aureus recognition by pattern recognition receptors known as Toll-like Receptors (TLR) is
likely due to ligand inaccessibility within the biofilm [69]. TLR binding and subsequent activation
potentiates phagocytosis and antimicrobial activity through oxidative burst mechanisms, thus the
arrangement of biofilms within a protective matrix serves to conceal internal components. Disruption
of P. aeruginosa biofilms to homogenised individual cells exhibited an increase in phagocytosis
demonstrating the importance of the protective nature of the biofilm matrix [67].
Understanding fundamental interactions between biofilms and the immune system presents
opportunities for novel control strategies. Glycolipids involved in quorum sensing produced by
P. aeruginosa, rhamnolipids, protects against neutrophil activity by inducing lytic necrosis [71].
Disruption of this protection via mutation or quorum inhibitors increases phagocytosis rates, thus
targeting active evasion mechanisms offers a route for innovative biofilm treatment strategies.
3. Guideline for Management of Biofilm Associated Infection
Tackling the central issue of HAI biofilms requires that diagnosis and treatment be collectively
examined (in a concerted manner) and selected to avoid senseless efforts and increase chances for
effective therapy. Several guidelines and recommendations are available for diagnosis and treatment
of biofilm infection [72,73] and are summarised in Table 2.
Table 2. Summary of guidelines for diagnosis and treatment of biofilm infections.
Steps Detail Action
Biofilm diagnosis
1. Sampling on tissue biopsy or device/prosthesis (foreign bodies).
2. Microbial cultivation and identification.
3. Antibiotic susceptibilities test.
Reporting of biofilm associated infections
Biofilm associated infections may be reported using descriptive terms.
1. Detected
e.g., ‘Microscopy shows Gram-negative rods in biofilm-like structures’
2. Suspected
e.g., ‘Growth of/PCR-detected microorganisms possibly from a biofilm infection’
Treatment of biofilm related infections
1. Removal sources of infections
1. Debridement of tissues
2. Removal of foreign bodies
2. Administration of topical antiseptics
1. Empiric therapy to prevent biofilm formation after debridement of tissues
2. Pre-emptive therapy to prevent possible biofilm reformation when specific
bacteria is detected from the debride tissue
3. Administration of antibiotics
1. Selection of antibiotics suitable for biofilm associated infections
2. Administration of antibiotics
3. Optimization of dosage
Monitoring
1. Assessment of wounds
2. Appropriate/maintenance debridement
3. Re-evaluation of antiseptics/antibiotics efficacy
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Table 2. Cont.
Steps Detail Action
Standard care 1. Set-up the advance therapies
2. Incorporation of novel techniques
Diagnosis and treatment of biofilm can be achieved by various methods, approaches in diagnosing and treating
biofilm infections will be further discussed in the following sections.
4. Diagnosis of Biofilm Mediated Infections
The diagnosis of biofilm-related infections is complex and should combine different approaches
and a multidisciplinary perspective from clinical and laboratory diagnosis [74]. The European Society
for Clinical Microbiology and Infectious Disease (ESCMID) has provided a detailed guideline to
aid clinicians in the diagnosis of biofilm related infections. Briefly the guideline emphasizes the
combination of clinical and laboratory diagnosis to facilitate clinicians in providing an effective
therapy to patients [73]. Generally, the clinical diagnosis may include clinical signs, case history,
failure of antibiotic therapy and persistent infection. For laboratory diagnosis, the following
techniques have demonstrated high efficacy, successfully discriminating between planktonic and
biofilm mediated infections.
4.1. Sonication
Sonication is a process that uses acoustic energy to agitate particles in a solution. This method is
useful and recommended to be applied to remove microbial biofilms from the biomaterial surface [75].
The suspected source of infection (e.g., implant) is removed from the patient and subjected for
sonication. The process disrupts strongly adhered biomass and releases the biofilm into the solution
allowing further analysis to further identify the microbial species [76]. Sonication has been shown to
be useful in removing biofilms from urinary catheters, cardiac implantable electronic devices, and
prosthetic implants [75–77].
4.2. Polymerase Chain Reaction (PCR)
PCR is one of the common methods used for detection of pathogens directly from clinical
specimens. The method is based on the amplification of specific conserved regions within the targeted
organism, providing high specificity and sensitivity in discriminating species of bacteria. Due to
the robustness of the method, PCR-based diagnostic tests have been used for detecting a range of
pathogens including bacteria, viruses, parasites, and fungi [78–81]. In biofilm diagnosis, PCR has been
applied to detect the microbial species that forms biofilms on tissues or biomaterials following the
sonication process. For example, PCR was used to detect coagulase negative staphylococci, S. aureus,
Cutibacterium species, Enterococci, and Candida spp. following sonication of implants in the case of
orthopedic hardware associated infections [77].
4.3. Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS)
In recent years, matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF MS) devices have become widely available, changing laboratory workflows for
identification of pathogens in most clinical microbiology laboratories [82]. The bacterial protein
profiles obtained from intact or cell extracts can be compared to a database of bacterial reference mass
spectra for rapid identification at the genus, species, and subspecies level [83]. Also, the method allows
for differentiation between planktonic and biofilm cells, as these two populations display different
spectra. The method has been tested in different species of Gram-positive and negative bacteria [84].
4.4. Fluorescence In Situ Hybridization (FISH)
FISH is a method that involves binding of short (between 18–25 base pairs), fluorescently
labeled oligonucleotides that can bind to the specific ribosomal RNA of the target organism (bacteria,
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protozoa, and yeast). Analysis involves visualization of targeted ribosomal RNA by fluorescence
microscopy [85]. This method can be applied directly on intact specimen fragments, without the need
for time consuming sub-culture. Identification of biofilms using FISH is further enhanced by the ability
to easily detect bacterial aggregation. The method has been successfully applied to detect biofilm of the
following bacteria: Streptoccous spp.; S. aureus; Gardnerella vaginalis; and Atopobium vaginae in vaginal
biofilms [85–88].
4.5. Microscopy
Microscopy is commonly used following the sonication or FISH to visualize the bacterial
aggregates in the specimen. Bacterial growth within biofilms are commonly found as aggregates
compared to individual dispersed cells observed during the growth of planktonic cells [85]. The most
common microscopy technique used to visualize microbial biofilms are scanning electron microscopy
(SEM), transmission electron microscopy (TEM), and scanning confocal laser microscopy (SCLM).
The high resolution provided by these techniques allows for depth analysis within the biofilm structure
and thus assists the diagnosis of infection mediated by microbial biofilm [89–91]. Table 3 summarizes
the common laboratory techniques employed to assist the diagnosis of biofilm mediated infections.
Table 3. The common laboratory techniques applied for laboratory diagnosis of biofilm mediated infections.
Biofilm Mediated Infections Bacterial Species Techniques References
Chronic otitis media S. pneumoniae, M. catarrhalis, P. aeruginosa, S.aureus, and K. pneumoniae PCR and SEM [92]
Periprosthetic Infection Coagulase-negative Staphylococci, Propionibacteriumspp., Streptococci and Enterococci Sonication & PCR [93]
Chronic wound P. aeruginosa and S. aureus TEM & FISH [93]
Catheter-associated infection E. coli Sonication & SEM [76]
Chronic rhinosinusitis S. aureus and P. acnes FISH [94]
Cystic fibrosis P. aeruginosa FISH and lightmicroscope [93]
5. The Potency of Existing Therapies against Microbial Biofilm
Existing antibiotics are useful resources for the treatment of infections with potential formation
of biofilm and are summarized in Table 4. Application of suitable antibiotics that are effective
against biofilm can improve the outcome, reduce relapse, and improve recovery of the patients.
Effective eradication of biofilms could be achieved with high doses of antibiotics, combined with
drugs that weaken the biofilm. Efficient treatment of biofilm infections demands a well-established
multidisciplinary collaboration which includes: removal of the infected foreign bodies, selection
of biofilm-active and -penetrating antibiotics, systemic or topical antibiotic administration in high
dosage combinations, and administration of anti-quorum sensing or biofilm dispersal agents [72].
Specifically, treatment of biofilms requires effective and well-penetrating antibiotics to ensure a
sufficient concentration of effective antibiotic at the site of biofilm infection. In general, macrolides,
lincosamides, tetracyclines, rifamycins, quinolones, fusidic acid, nitroimidazole, sulfonamides,
and oxazolidinones penetrate better in tissues and cells than beta-lactam (including penicillins,
cephalosporins, and carbapenems), aminoglycosides, glycopeptide, and polymyxin [72]. Antimicrobial
agents such as meropenem, colistin, and azithromycin are good candidates for combination strategies
which maintain their activity under conditions of reduced oxygen tension and low metabolic activity
as found in deeper layers of biofilms. Some of the widely used antibiotics such as azithromycin,
ceftazidime, and ciprofloxacin have Quorum Sensing Inhibitor (QSI) activity in addition to their
conventional antibiotic activity. An example of a drug that can be included in combination approaches
for P. aeruginosa biofilm infection is azithromycin. The drug has been shown to inhibit or reduce the
production of several of the virulence factors (elastase and rhamnolipids) of P. aeruginosa, as well as
the matrix component alginate as well as inhibiting quorum sensing. More drugs like azithromycin
are required, ideally with higher potency [95].
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Table 4. Summary of existing antibiotic regimens according to the specific microbial species.
Bacteria Biofilm Site of Infection Antibiotic Regimen Duration Route of Administration References
P. aeruginosa
Lung infection in cystic
fibrosis (CF)
0.5–2 MU colistin, twice daily Continuous
Inhalation [96]
300 mg tobramycin, twice daily 28 days on/off cycles
75 mg aztreonam, three times daily 28 days on/off cycles
32.5 mg or 65 mg ciprofloxacin, once daily 28 days
Lung infection in
non-CF
bronchiestasis
1 MU colistin, twice daily Continuous Inhalation [97]
32.5 mg ciprofloxacin, twice daily 28 days Inhalation [98]
P. aeruginosa and/or S. aureus Rhinosinusitis 3 drops ofloxacin 0.3%, three times daily 28 days Nasal drops [99]
S. aureus Wounds Mupirocin 2% ointment - Cutaneous [100]
S. aureus Catheters
50 mg/mL daptomycin
24 h Catheter lumen [101]10 mg/mL tigecycline
10 mg/mL rifampicin
10 mg/mL cotrimoxazole + 2500 U/mL heparin 12–24 h Catheter lumen [102]
Minocycline-rifampin - Coating [28]
K. pneumoniae Catheters doripenem and tobramycin - Catheter lumen [103]
P. aeruginosa Orthopedicprocedures
1 g tobramycin + 12 or 24 MU
colistin + 40 g polymethylmethacrylate -
Intraoperative
(PMMA beads) [104]
S. aureus Orthopedic procedures
40 mg/mL tobramycin + 1 g vancomycin + 10 mL
packet of calcium sulfate -
Intraoperative
(calcium sulfate beads) [104]
2 mg/mL gentamicin aqueous solution - Intraoperative(injection) [105]
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The current combination regimen recommended for the treatment of carbapenem-resistant
K. pneumoniae (CR-KP) includes high-dose carbapenem therapy (first-line antibiotic), which is combined
with colistin and or tigecycline, gentamicin, or fosfomycin (second-line antibiotics). Synergistic
interactions between the first-line and second-line antibiotics minimize the use of extremely high
doses and the emergence of resistance, as well as potentiate the effectiveness of individual agents.
Rifampicin is also occasionally considered for inclusion in combination regimens because of its ability
to penetrate intracellular sites and biofilms, which could be important in the treatment of CR-KP
infections involving prosthetic material. A new antimicrobial with activity against CR-KP, ceftolozone,
is a potent new cephalosporin that is not degraded by current AmpC cephalosporinases or affected by
known porin mutations and efflux pumps circulating in CR-KP strains. When tested in combination
with tazobactam, the drug has demonstrated promising activity in-vitro against multi-drug resistant
Gram-negative isolates, including CR-KP [72].
6. Promising Novel Therapies for Prevention and Treatment of Biofilm Associated Infections
6.1. Nanoparticles
Nanoparticles are particles that have an internal structural measurement or external dimensions
within the nanometers size and can be acquired from metallic, metal oxide, semiconductor, polymer, or
carbon-based materials [16,106]. There are two major groups of nanoparticles, organic (e.g., micelles,
dendrimers, liposomes, hybrid, and compact polymer) and inorganic nanoparticles (e.g., fullerenes,
quantum dots, silica, gold, and graphene) [107]. Nanoparticle-mediated antibacterial activities
depend on the composition, surface modification, intrinsic properties, and the bacterial species [108].
The reported mechanisms of antibacterial activities include disruption of the bacterial membrane,
condensation of the bacterial genome and induction of reactive oxygen species that can be harmful
to the physiology of the bacteria [109–111]. Graphene, one of the recently discovered nanoparticles,
exhibits antibacterial activity through direct interaction of the compound with the bacterial membrane,
causing stress to the membrane, releasing the intracellular contents and bacterial cell death [107].
Additionally, nanoparticles are reported to have anti-biofilm activities by effectively removing
and preventing formation of biofilm on surfaces. Table 5 summaries nanoparticles with anti-biofilm
activities. The mechanisms of nanoparticle anti-biofilm activity have only been partially understood.
For example, silver nanoparticles mediate anti-biofilm activity by suppressing the polysaccharide
intercellular adhesion (PIA) synthesis, thus preventing bacterial adhesion to surfaces [112]. On the
other hand, zinc oxide (ZnO) prevents biofilm formation by inhibiting microbial growth and prevents
biofilm to reach a steady state [113]. Additionally, Yadav et al. demonstrated that graphene oxide
coated on surfaces reduced attachment of bacteria, thus preventing biofilm formation [107].
Application of nanoparticles as an antibacterial provides several advantages compared to
conventional antibiotics. Nanoparticles have multiple modes of action and range of bacterial targets
which would require several bacterial mutations to resist antimicrobial activity. As such nanoparticles
present a considerable advantage over conventional antibiotics as they offer an option where there
is a reduced likelihood to develop resistance based on intrinsic properties [114]. This is especially
important when there is an increase of bacteria resistance of new strains against most potent antibiotics.
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Table 5. Examples of nanoparticles with anti-biofilm activities.
Type of Nanoparticles Microbial Biofilm References
Silver (immobilized on titanium) S. intermedius [112]
Silver P. aeruginosa, Shigella flexneri, S. aureus andS. pneumonia [115]
Titanium dioxide S. aureus and P. putida [116]
Selenium and selenium dioxide S. aureus, P. aeruginosa and Proteus mirabilis [117]
Zinc oxide and combination of
zinc oxide and hydroxyapatite Streptococcus sp. [113]
Graphene oxide E. coli and S. aureus [107]
6.2. Diterpenoids
Diterpenoids are a group of plant-derived metabolites composed of two terpene units with
molecular formula C20H32. Based on number of rings present in the molecular structure, diterpenoids
were classified into acyclic (e.g., phytanes), monocyclic (e.g., Cembrene A), bicyclic (e.g., labdanes,
halimanes, and clerodanes), tricyclic (e.g., pimaranes, abietanes, cassanes, and dehydroabietic
acid), tetracyclic (e.g., trachylobanes and kauranes,), and macrocyclic diterpenes (e.g., taxanes,
cembranes) [118]. These metabolites have shown potential values to substitute antibiotics for the
treatment of antibiotic-resistant and biofilm forming microbes such as S. aureus. Abietane-type
diterpenoids extracted from the root of Salvia sclarea, a medicinal plant used for easing stomach
ache, diarrhoea, sore throat swelling, and headaches, revealed microbicidal and microbiostatic activity
against S. aureus as well as acanthamoeba, a free-living amoeba. The active compound, salvipisone,
showed potential anti-biofilm activity against the antibiotic-resistant Staphylococci, greater than
most reported antibiotics [16]. Dehydroabietic acid (DA), an abietane-type diterpenoid found in
the resin of coniferous trees, is effective in the inhibition of S. aureus biofilm formation in the low
molar range, while the effective dose that reduced the viability and biomass of the formation of a
biofilm was just two to four-fold higher than the inhibitory dose [119]. Hybrids of DA and selected
amino acids resulted in potent fast-acting disassembly of biofilms and weakened the integrity of
the bacterial membrane. Also, the DA-amino acid hybrids are potentially more resistant against
proteolysis as compared to DA alone. The concentration of bactericidal dose is only three to six
folds higher than the bactericidal dose [120]. 8-hydroxyserrulat-14-en-19-oic acid, a plant-derived
serrulatane diterpenoid (extracted from the Australian medicinal plant Eremophila neglecta) showed
anti-biofilm formation activity against Gram-positive bacterial but not Gram-negative bacteria by
inhibiting the macromolecular biosynthesis of the bacterial membrane [121]. Table 6 summarises
examples of diterpenoids with anti-biofilm activities
Table 6. Examples of diterpenoids with anti-biofilm activities.
Type of Diterpenoids Microbial Biofilm Mechanism of Action (Hypothetical) References
Abietane (natural)
• salvipisone
• aethiopinone
S. aureus, S. epidermidis NA [14]
Abietane (synthetic)
• dehydroabietic acid scaffold
with different amino acids
S. aureus, S. epidermidis Bacterial membrane or the peptidoglycan(PG) layer [81]
Diterpene
• serrulatane compound
8-hydroxyserrulat-14-en-19-oic
acid (EN4)
S. aureus
(methicillin-susceptible
and methicillin-resistant),
S. epidermidis
Membranolytic properties as well as a
general inhibition of macromolecular
biosynthesis
[83]
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6.3. Biomacromolecules
Biomacromolecules such as polysaccharides, naturally secreted polymers, aliphatic, cyclic, and
aromatic organic acids were studied for their potential in preventing and constraining biofilm formation
or resolving the formed biofilm. Distinct from antibiotics, these macromolecules do not target specific
intracellular molecules within the microbes. Instead, with their amphiphilic characteristics, the cationic
group of the molecules facilitates microbial targeting and water solubility; while the hydrophobic
group induces membrane lysis; being attracted to the microbial membrane via interaction between
their cationic groups and the anionic membrane’s surface. Upon physical interaction, the hydrophobic
group penetrates the microbial membrane leading to membrane destabilization and cytoplasmic
content leakage. Antimicrobial agents with physical membrane disruption mechanisms are less likely
to be targeted by antimicrobial resistance [122]. Polysaccharides produced by a bacterium may affect
biofilm formation of other species through competition and cooperation phenomena [123]. For instance,
K. pneumoniae capsular polysaccharide was suggested to restrict biofilm formation in several clinically
important Gram-positive and Gram-negative bacterial species such as S. epidermidis, S. aureus, E. coli,
and Enterobacter aerogenes [124,125]. Extracellular polymeric substances such as natural high molecular
weight polymers secreted by bacteria have also been suggested to be anti-biofilm candidates [126].
Interruption of bacterial signaling systems such as quorum sensing affects bacterial biofilm formation.
In case of a mixed culture, acyl-homoserine lactonase produced by Bacillus cereus showed inhibition
and settlement of Vibrio cholera biofilm [127]. On the other hand, commercial organic acid products
usually used in food industry showed the ability to reduce Salmonella enterica viable count and biofilm
post-treatment, but not total elimination of the bacterium [128].
Incorporating macromolecules with anti-biofilm properties onto the surface of biomaterials has
gained increasing interest, especially in implant-associated medical devices such as intravascular
catheters, urinary catheters, and orthopedic implants [129]. Coating of biomaterial surface with
natural or modified polysaccharide polymers such as hyaluronic acid, heparin, and chitosan revealed
promising findings in battling implant-associated biofilm infections [130]. Table 7 summarises
examples of examples of biomacromolecules with anti-biofilm activities.
Table 7. Examples of biomacromolecules with anti-biofilm activities.
Type of Macromolecule Microbial Biofilm Mechanism of Action (Hypothetical) References
Polyether ether
ketone–octafluoropentyl methacrylate
surface
- Reduced protein adsorption [91]
AHL lactonase (AiiA), a
metallo-beta-lactamase produced by
Bacillus spp.
Vibrio cholerae
blocks quorum sensing in
Gram-negative bacteria by hydrolyzing
N-acyl-homoserine lactones (AHLs)
[89]
Chitosan-based surface coating S. aureus, S. epidermidis anti-adhesive and bactericidal viacontact membrane disruption [92]
K. pneumoniae capsular polysaccharide S. aureus, S. epidermidis, E. coli NA [87]
Commercially available organic acid
water additives Salmonella Typhimurium biofilms
Interference to intracellular pH
homeostasis, membrane structure,
osmolality and macromolecule
synthesis
[90]
Synthetic PDMEA MeI polymers S. epidermidis, S. aureus, E. coli andP. aeruginosa, Candida albicans Membrane disruption [84]
6.4. Honey
Honey, an ancient wound remedy has gathered renewed interest in its clinical potential for
inhibiting a wide range of infectious agents and promoting rapid wound healing [131]. The availability
of medical grade honey with laboratory proven effects at the cellular and molecular level against
certain microorganisms is not uncommon [131–134]. Mechanisms of bacterial inhibition within biofilm
formation attributed to honey is a particular focus due to the increasing multidrug resistance of
biofilm-associated organisms. Fortunately, there is accumulating evidence to show honey displays
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activity in both preventing the formation of a biofilm either through interfering with adherence to host
cells or interfering with quorum sensing and disrupting an established biofilm. Several types of honey
have been shown to exhibit anti-biofilm activity in-vitro (Table 8).
Besides being used alone, honey also exhibits synergistic activity in combination therapy with
certain antibiotics for planktonic cells [135–137]. Although promising, the application of honey as
an antibacterial, anti-biofilm, and wound healing promoting alternative is still primarily confined
to in-vitro testing. This is mainly due to the varying reports describing different sources of honey,
the strain of bacteria, biofilm stage, optimum dosage used, and wound/biotic conditions that might
influence the effectiveness of honey when being applied. A few in-vivo model using merino sheep
and albino mice demonstrated that anti-biofilm activity was found in honey used, but advised that
optimal clinical application should be titrated carefully as tissue toxicity and rejection of the necrosed
area from the epidermis was also found with increasing concentration [138,139]. However, care also
should be taken on the biofilm-enhancing action of low doses (<MIC) of honey that could be due to
a stress response, which has been observed when bacteria in biofilms are exposed to sub-inhibitory
concentrations of antibiotics [140].
Table 8. Examples of honey with anti-biofilm activity.
Type of Honey Microbial Biofilm Source
Manuka • P. aeruginosa, Streptococcus pyogenes, S. aureus, Klebsiella spp., Proteus
mirabilis *, E. coli, Acinetobacter baumannii, Clostridium difficile
[141–148]
Clover • P. aeruginosa, S. aureus, Klebsiella spp., Proteus mirabilis [141,149]
Pumpkin • Bacillus subtilis (B. subtilis) [150]
Chestnut and thyme • B. subtilis, S. aureus [150]
Euphorbia • B. subtilis, S. aureus, P. aeruginosa, E. coli [150,151]
Chaste • B. subtilis, S. aureus, S. epidermis [150]
Multifloral
• B. subtilis, S. aureus, S. epidermis
• Staphylococcus mutans
• Listeria monocytogenes
[150]
Eucalyptus • B. subtilis, S. aureus [150]
Honeydew • B. subtilis, S. aureus, S. epidermis, S. aureus, S. agalactiae, P. aeruginosa,
E. faecalis *
[145,150]
Lavender, strawberry
and citrus • P. aeruginosa, S. aureus & MRSA [152]
Sidr • P. aeruginosa, S. aureus, E. coli [151]
* With a certain degree of resistance.
6.5. Antimicrobial Peptides
Antimicrobial peptides (AMPs) are peptides molecules which are produced by many tissues and
cell types in a variety of invertebrate, plant, and animal species. The natural peptides are generally
made up of 10–50 amino acid residues, positively charged (+2 to +9), with around 50% of hydrophobic
properties and diverse sequences and structures [153]. The antimicrobial activities of these peptides
are attributed by the amino acid composition, ampipathicy, cationic charge, and size that allow them
to attach and insert themselves into the bacterial membrane bilayers to form pores and thus, kill the
bacteria [154]. Other than working effectively against planktonic bacterial cells, AMP has also been
shown to be effective against biofilms. Mataraci, 2012 evaluated the anti-biofilm activities of two
AMPs, indolicin and CAMA: cecropin (1–7)-melittin A (2–9) amide which was found to inhibit MRSA
biofilms formation [9]. Additionally other AMPs are currently highlighted as a promising approach to
prevent biofilm formation or to treat established biofilms, for instance, LL-37, HBD3, hep-20, IDR-1018
are able to inhibit several species of biofilm formation by either down-regulating the genes essential
for biofilm development or up-regulate the expression of genes resulting in a marked attenuation of
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biofilm production and even by altering the architecture and reducing the amount of extracellular
matrix [155–157]. AMPs also are known as host defense peptides are essential components of innate
immunity in higher organisms, contributing to the first line of defense against infections [158]. While
investigating possible anti-biofilm peptides from natural resources, synthetic peptides produced either
by de novo synthesis or by modification gained increased interest based on their improved biological
functions and reduced size, which in turn reduces production costs [159,160]. A curated list of useful
AMP along with their antimicrobial properties has been documented by de Luca and held within a
database called BaAMP accessed via www.baamps.it [161].
Several comprehensive works reviewing various aspects of AMPs have been performed [155–157].
Success of AMPs in both antimicrobial and anti-biofilm activities are collectively due to several
characteristics namely: (i) rapid bactericidal effects; (ii) high plasticity in different microenvironments;
(iii) good penetration into the matrix of extracellular polymeric substances (EPS); (iv) anti-quorum
sensing; (v) host response modulator; and (vi) synergistic effects with other conventional and
unconventional antimicrobial compounds [155]. The mechanisms exhibited by AMPs are illustrated in
a different state in Figure 4.
6.6. Antimicrobial Polymer
Antimicrobial polymers are synthetic polymers covalently linked with functional groups with
high antimicrobial activity such as amino, hydroxyl, and carboxyl groups [162]. Antimicrobial
polymers are effective against a range of bacteria including the bacteria commonly associated with
HAIs [163]. Due to the long and repeating chain of active and charged functional groups, the common
mechanism of antimicrobial activity is through disruption of the cell wall or cytoplasmic membranes.
Takahashi et al. demonstrated that cationic homopolymer PE0 and copolymer PE31 containing 31% of
ethyl methacrylate was effective in removing biofilm of Staphylococcus mutans (S. mutans) compared to
chlorohexidine and the cationic surfactant that was tested at the same concentration [162]. Another
study by Li et al. showed that cationic monomer, methacryloxylethylcetyl dimethyl ammonium
chloride (DMAE-CB) was also effective in the removal of a biofilm of S. mutans, the common bacteria
associated dental problems [164]. Peng et al. modified the polyurethane compound, the main
compound for catheter by copolymerization of an amine functionalized N-substituted diol to give
a cationic polyurethane (Tecoflex-NH3), and showed that the cationic polyurethane shown contact
killing of E. coli and prevent build-up of biofilm on the surfaces, thus, reducing the chances of CAUTI,
one of the main causes of the nosocomial infections [165]. Another example of an antimicrobial
polymer is Polyhexamethlene biguanide (PHMB), a cationic polymer that has been used in the clinic
for over than 40 years with no sign of bacterial resistance [166]. PHMB mediates antibacterial activities
through disruption of the cell wall and condensation of the bacterial chromosome [111], and recent
discovery demonstrate PHMB efficacy in killing intracellular bacteria [16,167]. PHMB is also effective
against biofilms from a range of bacterial species and thus effective when applied for the treatment of
wound infections [39,168,169]. Though there are increasing findings for polymer mediated anti-biofilm
activities, the complete mechanism of the activities is not fully understood. The anti-biofilm activities
posed by the polymers could possibly be due to the interaction of the charged group on the polymer
structure with the eDNA or Ca2+, thus disrupting the biofilm structure and cause destabilization.
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7. Summary and Outlook
Biofilms, a form of protective armour for the bacteria, are generally more resistant to the treatment.
Biofilms will remain a challenge for the prevention and control of infection; thus it is critical that
we continue to explore and understand the physiology and structure of biofilms to develop an
improved, innovative, and novel targeted therapies. Based on promising in-vitro studies and reports
investigating the use of nanoparticles, AMPs, diterpenoids, and biomacromolecules; we propose that
these compounds should be the focus of future novel biofilm control strategies. Further studies focusing
on the efficacy and tolerability in-vivo are required to ascertain the level of translation of in-vitro results
to clinical resolution of infections caused by biofilms. Together with the increased understanding of the
fundamental biology of biofilms, the application of novel or repurposed compounds will undoubtedly
improve the prospect of treating and resolving biofilm infection within clinical settings.
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